Market OpportunitiesTargeting international markets where semaglutide is not meaningfully patent-protected presents significant market opportunities for Galmed.

Partnerships And CollaborationsGalmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.

Bears Say

Clinical Development DelaysThe program is still relatively early stage and there will not be human clinical data until 1H26.

Financial ChallengesGalmed may also potentially require a capital raise to commence a clinical trial, and under current market conditions, financing will likely be difficult and significantly dilutive.

Galmed Pharmaceuticals News

Galmed Pharmaceuticals Amends Articles of Association Following Shareholder Approval

Galmed Pharmaceuticals ( ($GLMD) ) has issued an update. On August 15, 2025, Galmed Pharmaceuticals held a Special...

1d ago

GLMD

Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum

The latest update is out from Galmed Pharmaceuticals ( ($GLMD) ). On August 14, 2025, Galmed Pharmaceuticals Ltd....

2d ago

GLMD

Galmed Pharmaceuticals to Hold Special Meeting on Share Capital Increase

An update from Galmed Pharmaceuticals ( ($GLMD) ) is now available. Galmed Pharmaceuticals Ltd. announced a Special General...

23d ago

GLMD

Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential

An announcement from Galmed Pharmaceuticals ( ($GLMD) ) is now available. On May 27, 2025, Galmed Pharmaceuticals announced...

3M ago

GLMD

Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology

Galmed Pharmaceuticals ( ($GLMD) ) has issued an update. On May 22, 2025, Galmed Pharmaceuticals announced its financial...

3M ago

GLMD

Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models

Galmed Pharmaceuticals ( ($GLMD) ) just unveiled an announcement. On May 13, 2025, Galmed Pharmaceuticals announced significant findings...

3M ago

GLMD

Galmed’s Aramchol shows “significant” anti-fibrotic effects in PSC models

Galmed (GLMD) announced results showing significant effects of Aramchol in pre-clinical models of primary sclerosing cholangitis, or PSC....

3M ago

GLMD

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

PTN

BOLT

Galmed Pharmaceuticals Unveils Promising Oncology Study Results with Aramchol

Galmed Pharmaceuticals ( ($GLMD) ) just unveiled an announcement. On May 6, 2025, Galmed Pharmaceuticals announced significant results...

3M ago

GLMD

Galmed announces results from Aramchol studies

Galmed (GLMD) Pharmaceuticals announced that the first set of oncology studies has shown that Aramchol enhances the liver...

3M ago

GLMD

Galmed announces results from Aramchol studies

Galmed (GLMD) Pharmaceuticals announced that the first set of oncology studies has shown that Aramchol enhances the liver...

3M ago

GLMD

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

NVS

BCDA

3 Penny Stocks to Watch Now, 4/29/25

AGM Group Holdings, Odyssey Marine Exploration, and Galmed Pharmaceuticals are the 3 Penny Stocks to watch on April 29, 2025,...

4M ago

AGMH

GLMD

Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation

An announcement from Galmed Pharmaceuticals ( ($GLMD) ) is now available. On April 28, 2025, Galmed Pharmaceuticals announced...

4M ago

GLMD

GLMD FAQ

What was Galmed Pharmaceuticals’s price range in the past 12 months?

Galmed Pharmaceuticals lowest stock price was $1.15 and its highest was $23.80 in the past 12 months.

What is Galmed Pharmaceuticals’s market cap?

Galmed Pharmaceuticals’s market cap is $3.34M.

When is Galmed Pharmaceuticals’s upcoming earnings report date?

Galmed Pharmaceuticals’s upcoming earnings report date is May 20, 2026 which is in 276 days.

How were Galmed Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Galmed Pharmaceuticals overvalued?

According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Galmed Pharmaceuticals pay dividends?

Galmed Pharmaceuticals does not currently pay dividends.

What is Galmed Pharmaceuticals’s EPS estimate?

Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals has 2,258,034 shares outstanding.

What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Galmed Pharmaceuticals?

Currently, no hedge funds are holding shares in GLMD

Company Description

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.